Indication |
Used mainly to produce mydriasis and cycloplegia for diagnostic purposes. |
Pharmacodynamics |
Cyclopentolate is an anti-muscarinic in the same class as
atropine and scopolamine. Cyclopentolate blocks the receptors in the
muscles of the eye (muscarinic receptors). These receptors are involved
controlling the pupil size and the shape of the lens. Cyclopentolate
thus induces relaxation of the sphincter of the iris and the ciliary
muscles. When applied topically to the eyes, it causes a rapid, intense
cycloplegic and mydriatic effect that is maximal in 15 to 60 minutes;
recovery usually occurs within 24 hours. The cycloplegic and mydriatic
effects are slower in onset and longer in duration in patients who have
dark pigmented irises. |
Mechanism of action |
By blocking muscarinic receptors, cyclopentolate produces
dilatation of the pupil (mydriasis) and prevents the eye from
accommodating for near vision (cycloplegia). |
Absorption |
Absorbed following ophthalmic administration. |
Volume of distribution |
Not Available |
Protein binding |
Not Available |
Metabolism |
Not Available |
Route of elimination |
Not Available |
Half life |
Not Available |
Clearance |
Not Available |
Toxicity |
Oral LD50 in the rat is 4000 mg/kg and 960 mg/kg in the
mouse. Symptoms of overdose include tachycardia, dizziness, dry mouth,
behavioral disturbances, uncoordination and drowsiness. |
Comments
Post a Comment